The abstract is read at the publisher; the summary is JClub's.
TRACE reconstructs monotonic biomarker trajectories and jointly infers disease subtypes and continuous stages from sparse cross-sectional and limited longitudinal evidence, enabling clinically meaningful staging.
- Why it matters: Chronic progressive diseases show heterogeneous biomarker timing, but sparse observations and short follow-up make it hard to separate stage effects from subtype differences.
- What they did: TRACE is a probabilistic framework that uses monotonic neural networks plus data-driven clustering of subtype-specific progression, with temporal regularization from longitudinal data when available, optimized end to end via stochastic gradient descent.
- The result: In semi-simulated MRI biomarker data with known subtype and stage structures and in real-world neurodegenerative disease datasets, TRACE identifies clinically meaningful subtypes and disease stages.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.